From Financial Modeling Prep: 2025-01-30 00:00:04

AbbVie Inc. is set to release its Q4 2024 earnings, with investors focusing on the performance of key drugs Rinvoq and Skyrizi. Revenue and EPS estimates are expected to be surpassed, with a history of exceeding expectations. Analysts predict growth driven by successful products despite setbacks in trials and high debt-to-equity ratio.

Wall Street analysts anticipate AbbVie will exceed revenue and EPS estimates for Q4 2024, driven by Skyrizi, Rinvoq, and neuroscience products. Despite challenges with emraclidine, the company remains committed to its development. Financial metrics show a high P/E ratio of 60.53 and significant leverage, but a current ratio suggests the ability to cover liabilities.



Read more at Financial Modeling Prep:: AbbVie Inc. (NYSE:ABBV) Earnings Preview: Key Insi…